Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia

被引：2
|
作者：
Zhang, Tongtong [1 ,2 ]
Zhou, Haixia [1 ,2 ]
Xu, Mingzhu [1 ,2 ]
Qian, Chongsheng [1 ,2 ]
Sun, Aining [1 ,2 ]
Wu, Depei [1 ,2 ]
Xue, Shengli [1 ,2 ]
机构：
[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou 215000, Peoples R China
[2] Soochow Univ, Inst Blood & Marrow Transplantat, Collaborat Innovat Ctr Hematol, Suzhou 215000, Peoples R China
来源：
ANNALS OF HEMATOLOGY | 2023年 / 102卷 / 04期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1007/s00277-023-05110-y
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：973 / 975
页数：3
相关论文
共 50 条
  • [1] Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia
    Tongtong Zhang
    Haixia Zhou
    Mingzhu Xu
    Chongsheng Qian
    Aining Sun
    Depei Wu
    Shengli Xue
    Annals of Hematology, 2023, 102 : 973 - 975
  • [2] Combination of Liposomal Mitoxantrone, Venetoclax, Homoharringtonine, and Olverembatinib (HQP1351) (MVHO) in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML): Case Series
    Hu, Wenting
    Wang, Zhuo
    Chen, Changcheng
    Shen, Shuhong
    BLOOD, 2023, 142
  • [3] Olverembatinib (HQP1351) in Combination with Lisaftoclax Overcomes Venetoclax Resistance in Preclinical Model of Acute Myeloid Leukemia (AML)
    Xiong, Yan
    Liang, Zhiyan
    Min, Ping
    Wu, Bingxing
    Yu, Huidan
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2024, 144 : 5777 - 5778
  • [4] Exposure-Response (E-R) Analysis of Olverembatinib (HQP1351) in Chinese Patients with Chronic Myeloid Leukemia (CML)
    Lu, Ming
    Deng, Chenhui
    Xiong, Yifeng
    Wang, Hengbang
    Xu, Ping
    Men, Lichuang
    Xie, Tanhong
    Jiang, Qian
    Chen, Zi
    Niu, Qian
    Liu, Ping
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2020, 136
  • [5] Olverembatinib(HQP1351)-Based Therapy in Adults with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Advanced Chronic Myeloid Leukemia: Results of the Real-Life Study
    Wen, Ziyu
    Fan, Zhiping
    Wang, Qiang
    Zhou, Xuan
    He, Zherou
    Gao, Zicheng
    Chen, Hong
    Liang, Hanyin
    Luo, Dongmei
    Liu, Xiaoli
    Zhou, Hongsheng
    Liu, Qifa
    Xu, Na
    BLOOD, 2023, 142
  • [6] Genetic Profile of Mixed-Phenotype Acute Leukemia with BCR::ABL1/ Mixed-phenotype Blast Phase of Chronic Myeloid leukemia
    Hu, Shimin
    Lai, Xiaoxuan
    Hu, Collin
    Wang, Wei
    Loghavi, Sanam
    Medeiros, L. Jeffrey
    Tang, Guilin
    LABORATORY INVESTIGATION, 2024, 104 (03) : S1415 - S1415
  • [7] Olverembatinib (HQP1351) Overcomes Ponatinib and/or Asciminib Resistance in Patients With Heavily Pretreated/ Refractory Chronic Myeloid Leukemia (CML) and Philadelphia ChromosomePositive Acute Lymphoblastic Leukemia (Ph+ ALL)
    Jabbour, Elias
    Oehler, Vivian G.
    Koller, Paul B.
    Jamy, Omer
    Lomaia, Elza
    Hunter, Anthony M.
    Uspenskaya, Olga
    Samarina, Svetlana
    Mukherjee, Sudipto
    Cortes, Jorge E.
    Baer, Maria R.
    Zherebtsova, Vera
    Shuvaev, Vasily
    Turkina, Anna
    Davydkin, Igor
    Guo, Huanshan
    Chen, Zi
    Fu, Tommy
    Jiang, Lixin
    Wang, Cunlin
    Wang, Hengbang
    Yang, Dajun
    Zhai, Yifan
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S371 - S371
  • [8] Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL)
    Jabbour, Elias
    Koller, Paul B.
    Oehler, Vivian G.
    Jamy, Omer H.
    Mukherjee, Sudipto
    Hunter, Anthony M.
    Baer, Maria R.
    Beck, Joseph T.
    Chen, Zi
    Guo, Huanshan
    Fu, Lei
    Men, Lichuang
    Wang, Hengbang
    Yang, Dajun
    Zhai, Yifan
    Kantarjian, Hagop
    Jiang, Lixin
    Wang, Cunlin
    BLOOD, 2022, 140
  • [9] Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases
    Wang, Na
    He, Jing
    Liu, Fang
    CHEMOTHERAPY, 2022, 67 (03) : 178 - 182
  • [10] Safety and Efficacy of Olverembatinib (HQP1351) Combined with Lisaftoclax (APG-2575) in Children and Adolescents with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (R/R Ph plus ALL): First Report from a Phase 1 Study
    Zhang, Jingliao
    Wang, Junxia
    Guo, Huanshan
    Liu, Tianfeng
    Zhang, Xiaoyan
    Zhang, Ranran
    Ruan, Min
    Chang, Lixian
    Liu, Xiaoming
    Ren, Yuanyuan
    Chen, Xia
    Wang, Hengbang
    Chen, Zi
    Zhang, Yingchi
    Chen, Yumei
    Zhang, Li
    Guo, Ye
    Liu, Fang
    Chen, Xiaojuan
    Zou, Yao
    Yang, Wenyu
    Zhai, Yifan
    Zhu, Xiaofan
    BLOOD, 2024, 144 : 1443 - 1444
12345